Poxel S.A.
Records under this name other than the patents Poxel S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 17 patents it holds.
Showing 1 to 8 of 8 · Back to Poxel S.A.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,576,071 | Deuterium-enriched pioglitazone Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,141,411 | Methods of Treating Neurological, Metabolic, and Other Disorders Using Enantiopure Deuterium-Enriched Pioglitazone Formerly held In force · High confidence | In force | High confidence | |
| US 8,791,115 | Combination of Triazine Derivatives and Insulin Sensitisers Lapsed on the fee record Ended Jul 29, 2026 · High confidence | Lapsed on the fee record | Ended Jul 29, 2026 | High confidence |
| US 8,592,370 | Combination of insulin with triazine derivatives Lapsed on the fee record Ended Nov 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 26, 2025 | From the USPTO record |
| US 8,461,331 | Method for the production of 3,6-dihydro-L, 3, 5-triazine derivatives from metformin and paraldehyde derivatives Lapsed on the fee record Ended Jun 11, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 11, 2025 | From the USPTO record |
| US 7,501,511 | Process for Resolving Aimines That Are Useful for the Treatment of Disorders Associated with Insulin Resistance Syndrome Term ended Term ended Oct 28, 2024 · High confidence | Term ended | Term ended Oct 28, 2024 | High confidence |
| US 8,227,465 | Combination of triazine derivatives and insulin secretion stimulators Lapsed on the fee record Ended Jul 24, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jul 24, 2024 | From the USPTO record |
| US 8,217,040 | Use of Triazine Derivatives for the Manufacture of a Medicament Having a Cicatrising or Angiogenic Effect Lapsed on the fee record Ended Jul 10, 2024 · High confidence | Lapsed on the fee record | Ended Jul 10, 2024 | High confidence |